180 related articles for article (PubMed ID: 22462315)
1. Growing pains. Insurers and PbMs want in on 340B savings.
Lee J
Mod Healthc; 2012 Mar; 42(11):10. PubMed ID: 22462315
[No Abstract] [Full Text] [Related]
2. Plastic price cuts? Drug discount cards shave but don't slash high bills. And most aren't free.
Comarow A
US News World Rep; 2002 Apr; 132(12):74-6. PubMed ID: 11974551
[No Abstract] [Full Text] [Related]
3. Tips for preparing for a 340B integrity audit.
Wood W; Jorgenson J; Kelly W
Healthc Financ Manage; 2012 Dec; 66(12):50-2. PubMed ID: 23252228
[TBL] [Abstract][Full Text] [Related]
4. Provider-administered drugs move to specialty pharmacy benefit.
Manag Care; 2014 Apr; 23(4):49. PubMed ID: 24864535
[No Abstract] [Full Text] [Related]
5. 340B program presents opportunities--and challenges.
Keough CL; Webster SA
Healthc Financ Manage; 2009 Nov; 63(11):42-4, 46, 48. PubMed ID: 19891397
[TBL] [Abstract][Full Text] [Related]
6. The association of insurance type with costs of dispensed drugs.
Mott DA; Kreling DH
Inquiry; 1998; 35(1):23-35. PubMed ID: 9597015
[TBL] [Abstract][Full Text] [Related]
7. Estimating a reasonable reimbursement for community pharmacies in third-party programs.
Carroll NV
Manag Care Interface; 1999 Feb; 12(2):73-6, 79-80. PubMed ID: 10346189
[TBL] [Abstract][Full Text] [Related]
8. Price pressure. As the number of costly specialty drugs grows, insurers and providers push for more reasonable alternatives.
Evans M
Mod Healthc; 2013 Jan; 43(4):6-7, 16, 1. PubMed ID: 23488108
[TBL] [Abstract][Full Text] [Related]
9. State insurance commissioners weigh PBM regulations this month.
Carlson B
Manag Care; 2000 Mar; 9(3):19-20. PubMed ID: 11066209
[No Abstract] [Full Text] [Related]
10. Plans confront specialty pharmacy's escalating costs in variety of ways.
Reinke T
Manag Care; 2010 Dec; 19(12):12-3, 15-6, 19. PubMed ID: 21291126
[No Abstract] [Full Text] [Related]
11. Pharmaceuticals and medical devices: cost savings.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-20. PubMed ID: 19297717
[No Abstract] [Full Text] [Related]
12. Employer and Plan Sponsor Views on Pharmacy Reimbursement.
Stull M; Gupton C
J Manag Care Spec Pharm; 2020 Jun; 26(6):710-712. PubMed ID: 32463776
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-23. PubMed ID: 18345558
[No Abstract] [Full Text] [Related]
14. Pharmaceuticals and Medical Devices: Cost Savings.
Steiner DJ;
Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-31. PubMed ID: 28252884
[No Abstract] [Full Text] [Related]
15. Fresh Approaches to Addressing High Drug Costs.
Armstrong J; Becker C
NCSL Legisbrief; 2019 Apr; 27(15):1-2. PubMed ID: 30990598
[No Abstract] [Full Text] [Related]
16. HEW promotes wider use of generic drugs, predicts savings under reimbursement plan.
Hospitals; 1979 Feb; 53(3):17. PubMed ID: 759296
[No Abstract] [Full Text] [Related]
17. Incentives in the Medicare prescription drug benefit.
Natl Bur Econ Res Bull Aging Health; 2006; (15):1-2. PubMed ID: 16805056
[No Abstract] [Full Text] [Related]
18. Unlock savings through innovative pharmacy benefit design.
Edlin M
AHIP Cover; 2005; 46(4):14-20. PubMed ID: 16149655
[No Abstract] [Full Text] [Related]
19. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-27. PubMed ID: 18345555
[No Abstract] [Full Text] [Related]
20. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
[No Abstract] [Full Text] [Related]
[Next] [New Search]
